目的：探讨视网膜光凝分别联合雷珠单抗与康柏西普治疗对视网膜静脉阻塞(retinal vein occlusion，RVO)继发黄斑水肿(macular edema，ME)患者黄斑中心厚度、视力恢复和不良反应的影响。

方法：将我院接诊的384例384眼RVO-ME患者分为A组(205例)和B组(179例)，A组接受视网膜光凝联合雷珠单抗玻璃体腔注射治疗，B组接受视网膜光凝联合康柏西普玻璃体腔注射治疗，比较两组患者术后黄斑中心凹视网膜厚度(central macular thickness，CMT)、最佳矫正视力(best corrected visual acuity，BCVA)、眼压(intraocular pressure，IOP)、不良事件等情况。

结果：两组患者术后3mo荧光素眼底血管造影(fundus fluorescein angiography，FFA)总有效率比较，差异无统计学意义(P>0.05)。两组患者各时间点BCVA比较，差异有统计学意义(P<0.05)； 两组患者组间BCVA比较，差异无统计学意义(P>0.05)； 两组患者术后BCVA均呈升高趋势(P<0.05)。两组患者各时间点CMT比较，差异有统计学意义(P<0.05)； 两组患者组间CMT比较，差异无统计学意义(P>0.05)； 两组患者术后CMT均呈下降趋势(P<0.05)。两组患者各时间点IOP比较，差异无统计学意义(P>0.05)； 两组患者组间IOP比较，差异无统计学意义(P>0.05)； 两组患者术后IOP均无显著升高(P>0.05)。B组3mo内注药次数明显少于A组(P<0.05)，两组患者不良事件总发生率比较，差异无统计学意义(5.4%vs 4.5%，P>0.05)。

结论：视网膜光凝联合雷珠单抗或康柏西普玻璃体腔注射均能控制RVO-ME患者病情，促进ME吸收，降低CMT，改善患者视力，两种药物单次给药作用时间有效，在给药次数方面，康柏西普优于雷珠单抗。

METHODS: Totally 384 cases of patients(384 eyes)with RVO-ME in our hospital were divided into Group A(205 cases)and Group B(179 cases). Group A was given retinal photocoagulation and ranibizumab intravitreal injection, and Group B was given retinal photocoagulation and conbercept intravitreal injection. The postoperative central macular thickness(CMT), best corrected visual acuity(BCVA), intraocular pressure(IOP)and adverse reactions were compared between the two groups.

RESULTS:There was no significant difference in the total effective rate of fundus fluorescein angiography(FFA)between the two groups after 3mo(P>0.05). There were significant differences in BCVA in the two groups at each time point(P<0.05). There was no significant difference in BCVA between the two groups(P>0.05). The BCVA in two groups showed an upward trend after operation(P<0.05). There was a statistically significant difference in MCT in the two groups at each time point(P<0.05). There was no significant difference in MCT between the two groups(P>0.05). The MCT showed a downward trend in two groups after operation(P<0.05). There was no significant difference in IOP in the two groups at each time point(P>0.05). There was no significant difference in IOP between the two groups(P>0.05). And there was no significant increase in IOP after operation(P>0.05). The drug injection frequency within 3mo in Group B was significantly less than that in Group A(P<0.05), and there was no significant difference in the total incidence rate of adverse reactions between the two groups(5.4% vs 4.5%, P>0.05).

CONCLUSION: Retinal photocoagulation combined with ranibizumab or conbercept intravitreal injection can control the condition of RVO-ME patients, promote ME absorption, reduce CMT and improve visual acuity. The two drugs have effective time in single administration, and the drug administration frequency of conbercept are better than those of ranibizumab.